| Recruiting | Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Pat NCT06615752 | Charles Drew University of Medicine and Science | Phase 1 / Phase 2 |
| Not Yet Recruiting | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer NCT07493512 | Amgen | Phase 1 |
| Recruiting | AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) NCT07285694 | Arsenal Biosciences, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Can NCT07310355 | Chengdu StarRay Therapeutics Co., Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer NCT07244393 | Cellbion Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) NCT07103018 | K36 Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Memantine Hydrochloride in Prostate Cancer Patients NCT07164794 | Bin Xu | Phase 2 |
| Active Not Recruiting | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus NCT06894511 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | 3D1015 Injection for Patients With mCRPC NCT07537010 | Chunjing Yu | Phase 1 |
| Not Yet Recruiting | Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate C NCT07104617 | TYK Medicines, Inc | Phase 1 / Phase 2 |
| Unknown | The Safety and Dosimetry Study of 177Lu-LNC1003 Injection NCT06237491 | Yantai LNC Biotechnology Singapore PTE. LTD. | Phase 1 |
| Not Yet Recruiting | A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Parti NCT06890832 | Jina Pharmaceuticals Inc. | Phase 2 |
| Not Yet Recruiting | Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castra NCT06827080 | Zhengguo Chen | Phase 1 / Phase 2 |
| Completed | Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate C NCT06377683 | The First Affiliated Hospital of Xiamen University | Phase 1 |
| Recruiting | Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired an NCT06004661 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors NCT06334432 | Nuvation Bio Inc. | Phase 1 / Phase 2 |
| Recruiting | A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC NCT06241846 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 2 |
| Recruiting | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castrat NCT06136650 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer NCT05806814 | University of Oklahoma | Phase 1 |
| Recruiting | Combination Study of Antibiotics With Enzalutamide (PROMIZE) NCT06126731 | Institute of Cancer Research, United Kingdom | Phase 1 / Phase 2 |
| Recruiting | Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T NCT06134232 | Dendreon | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adul NCT05670106 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment N NCT05658003 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland NCT05701007 | Pfizer | — |
| Active Not Recruiting | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 NCT05579184 | FutureChem | Phase 2 |
| Suspended | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer NCT05425862 | Peter MacCallum Cancer Centre, Australia | Phase 1 |
| Unknown | Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCR NCT06344715 | SL VAXiGEN | Phase 1 |
| Active Not Recruiting | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies NCT05032040 | Xencor, Inc. | Phase 2 |
| Recruiting | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors NCT05176483 | Exelixis | Phase 1 |
| Recruiting | A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674 | Nurix Therapeutics, Inc. | Phase 1 |
| Completed | Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resista NCT04862091 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abira NCT04691804 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Terminated | The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Mem NCT05208229 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Active Not Recruiting | PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA NCT04015622 | British Columbia Cancer Agency | Phase 2 |
| Completed | EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contrib NCT04516161 | Bayer | — |
| Terminated | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tu NCT04052204 | Pfizer | Phase 1 / Phase 2 |
| Completed | An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer NCT04089553 | AstraZeneca | Phase 2 |
| Recruiting | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemipl NCT03972657 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer NCT03874884 | Peter MacCallum Cancer Centre, Australia | Phase 1 |
| Completed | Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts NCT03896984 | Bayer | — |
| Terminated | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency NCT03712930 | BeiGene | Phase 2 |
| Recruiting | ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer NCT03903835 | Karolinska Institutet | Phase 3 |
| Completed | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors NCT03811652 | MedImmune LLC | Phase 1 |
| Completed | Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled A NCT03724747 | Bayer | Phase 1 |
| Terminated | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Mal NCT03549000 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and NCT03460977 | Pfizer | Phase 1 |
| Completed | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers NCT03071328 | Duke University | EARLY_Phase 1 |
| Completed | ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer NCT03480646 | Constellation Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostat NCT03030885 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Ind NCT02649790 | Karyopharm Therapeutics Inc | Phase 1 / Phase 2 |
| Completed | Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-res NCT03074032 | Avionco LLC | Phase 1 |
| Withdrawn | Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or En NCT02130947 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Completed | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Ca NCT01977651 | Astellas Pharma Global Development, Inc. | Phase 4 |
| No Longer Available | 177Lu-PSMA-617 Managed Access Program for mCRPC Patients NCT04825652 | Advanced Accelerator Applications | — |